| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD37 |
| Uniprot No | P11049 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 112-241aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSQ RAQLERSLRDVVEKTIQKYGTNPE ETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAHRVPCSCYNLS ATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGLQ KWLHNN |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD37重组蛋白的3篇参考文献概览(基于近年研究主题模拟，非真实文献)：
---
1. **文献名称**：*CD37 Recombinant Protein as a Therapeutic Target in B-cell Malignancies*
**作者**：Smith A, et al.
**摘要**：研究团队通过重组表达人源CD37蛋白，验证其作为B细胞淋巴瘤免疫治疗靶点的潜力。实验证明，CD37重组蛋白可特异性结合单克隆抗体，并在体外抑制肿瘤细胞增殖，为抗体药物开发提供基础。
---
2. **文献名称**：*Expression and Purification of Soluble CD37 in Mammalian Cells for Structural Studies*
**作者**：Li J, et al.
**摘要**：报道了一种利用HEK293细胞高效表达可溶性CD37重组蛋白的方法，并通过亲和层析纯化获得高纯度蛋白。该研究解析了CD37胞外域的结构，揭示了其与免疫细胞表面受体的相互作用机制。
---
3. **文献名称**：*CD37-based Fusion Protein Enhances Antitumor Immunity in Solid Tumors*
**作者**：Garcia-Ruiz C, et al.
**摘要**：构建了CD37重组蛋白与免疫检查点抑制剂(如PD-1)的融合蛋白，在动物模型中证实其能同时靶向肿瘤微环境中的T细胞和B细胞，显著增强抗肿瘤免疫应答，为联合疗法提供新思路。
---
(注：以上文献为示例性内容，实际研究中请通过PubMed或Web of Science检索真实文献。)
CD37. a member of the tetraspanin transmembrane protein family, is primarily expressed on the surface of immune cells, particularly B cells and subsets of T cells and dendritic cells. Characterized by four transmembrane domains forming distinct structural loops, CD37 plays critical roles in cell adhesion, migration, signaling, and immune regulation. It interacts with integrins, MHC molecules, and other tetraspanins to modulate immune responses and maintain cellular microenvironments. Dysregulation of CD37 has been implicated in B-cell malignancies, autoimmune diseases, and immune evasion mechanisms in cancers.
Recombinant CD37 protein is engineered using expression systems like mammalian cells (e.g., HEK293 or CHO) or *E. coli* to produce soluble forms of the extracellular domains (typically the large extracellular loop, LEL). The mammalian system ensures proper post-translational modifications, including glycosylation, which may influence protein stability and functional studies. The recombinant protein is purified via affinity tags (e.g., His-tag or Fc-fusion) and validated through SDS-PAGE, Western blot, and mass spectrometry.
This protein serves as a vital tool for investigating CD37's biological functions, including ligand-receptor interactions and its role in tumor microenvironments. It is widely used to generate antibodies for diagnostic assays (e.g., flow cytometry, IHC) and therapeutic development, particularly in targeting CD37-expressing lymphomas. Recent research explores its potential as a biomarker or immunotherapeutic target, with clinical trials evaluating CD37-directed CAR-T cells and antibody-drug conjugates. Its recombinant form also aids in studying immune cell communication and validating drug candidates in preclinical models.
×
